Rex Mowat is an Oncology physician affiliated with Toledo Clinic Cancer Center. OpenAlex indexes 75 publications with 1,675 citations (h-index 21).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4235 Secor Rd
Toledo, OH 436234231
Telephone
419-479-5605Provider last certified this registry record 5 Feb 2026.
Industry payments
46 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Geron CorporationProgram year20251 payment
- Daiichi Sankyo Inc.Program year20252 payments
- GENZYME CORPORATIONProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
65.9%Iron, parenteral preparations63.1%Ferric carboxymaltose100%Part B, office-administered≥43 patientsErythropoiesis-stimulating Agent2.8%Epoetin alfa100%Part B, office-administered≥14 patients+ 2 more classes in this area
Cancer & immunology
15.6%PD-1 inhibitor15%Pembrolizumab100%Part B, office-administered≥16 patientsAromatase Inhibitor0.3%Anastrozole64%Letrozole30%Exemestane6%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
7.4%Substance P/Neurokinin-1 Receptor Antagonist6.4%Aprepitant100%Part B, office-administered≥12 patientsSerotonin-3 Receptor Antagonist1%Palonosetron hcl64%Palonosetron hydrochloride34%Ondansetron Odt2%Part D + Part B≥21 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2010–2014 per NIH RePORTER. The latest:
- TOLEDO COMMUNITY CLINICAL ONCOLOGY PROGRAM
Toledo Community Hospital Oncology Prog
FY2014$346,487U10CA035415 - TOLEDO COMMUNITY CLINICAL ONCOLOGY PROGRAM
Toledo Community Hospital Oncology Prog
FY2013$676,878U10CA035415 - TOLEDO COMMUNITY CLINICAL ONCOLOGY PROGRAM
Toledo Community Hospital Oncology Prog
FY2012$700,123U10CA035415
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”